DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Landscape & Forecast – Disease Landscape & Forecast (G7)
The non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) therapy market is rapidly evolving as novel agents provide alternatives to conventional chemoimmunotherapy regimens. This…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Acute Myeloid Leukemia – Landscape & Forecast – Disease Landscape & Forecast (G7)
Acute myeloid leukemia (AML) is associated with poor outcomes and low five-year overall survival rates. Although chemotherapy has long been the mainstay of AML treatment, the recent approval of new…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)
The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…
Multiple Myeloma – Geographic Focus: China – Multiple Myeloma – China In-Depth (China)
China’s multiple myeloma therapy market is evolving rapidly, driven by an increasing disease burden and advances in treatment options. Current therapies in China largely mirror global standards;…
